Clinical trials: Genome
Solid Tumor, Metastatic Cancer
A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre
The project, called "BALLETT" (Belgian Approach of Local Laboratory Extensive Tumor Testing), has a double goal: (1) show the relevance of broad molecular profiling to improve oncological patients care, (2) demonstrate that broad…
- Trial name
- BALLETT (NCT05058937)
- Testing
- Comprehensive genomic profiling
- Where
- 12 sites in Belgium
- Volunteers
- 936 people
- Sponsor
- The Belgian Society of Medical Oncology
HIV Infections, Healthy
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between…
- Trial name
- NCT04920539
- Testing
- Active Delta-9-THC
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Yale University
Subarachnoid Hemorrhage, Aneurysmal, Cerebral Vasospasm
Magnesium Treating Subarachnoid Hemorrhage Vasospasm
A randomized clinical trial investigating magnesium sulphate ability to reduce risk of cerebral vasospasm after acute subarachnoid hemorrhage hence improving outcome particularly in haptoglobin 2-2 patients who are highly…
- Trial name
- MATSH-SHapE (NCT04613960)
- Testing
- Magnesium sulfate, normal saline
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Prostate Cancer
Casodex/Zoladex Biomarkers in Localised Prostate Cancer
To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones
- Trial name
- NCT00293696
- Testing
- bicalutamide (Casodex), goserelin (Zoladex)
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Tampere University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination…
- Trial name
- NCT02589496
- Testing
- pembrolizumab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Microsatellite Instability, Lynch Syndrome
MSI in Circulatory DNA of Endometrial Cancer
This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer.
- Conditions
- Microsatellite Instability, Lynch Syndrome, Endometrial Cancer, Circulating Tumor Cell
- Trial name
- NCT03744962
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Single-Gene Disease
Analysis of Human Genomic DNA in Embryo's Culture Media
try to find genomic DNA in culture medium after the embryos develop on Day 3 and Day 5 also in single step culture media. using direct PCR Polymerase Chain Reaction and also WGA Whole Genome Amplification before PCR and…
- Trial name
- NCT02359747
- Testing
- Polymerase Chain Reaction and Whole Genome Amplification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Cervesi Hospital, Cattolica, Italy
Solid Tumor
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment…
- Trial name
- NCT05585684
- Testing
- Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Pregnancy Loss(RPL)
Genomics and Microbiome Investigation in Cases of Recurrent Pregnancy Losses
Recurrent pregnancy losses (RPL) are characterized by the occurrence of more than one spontaneous pregnancy loss. It is caused by different known factors, but about half of the cases remain without an explanation.
- Trial name
- NCT06604338
- Testing
- Exome test, Microbiota analysis
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Epithelial Ovarian Cancer, Nucleotide Variant
Genetic Mutation in Epithelial Ovarian Cancer
Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than…
- Conditions
- Epithelial Ovarian Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation
- Trial name
- NCT04191252
- Testing
- A multi-gene panel testing
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Lei Li
Transfusion Dependent Beta-thalassemia
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age.
- Trial name
- NCT03432364
- Testing
- ST-400 Investigational product
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sangamo Therapeutics
Recurrent Endometrial Cancer
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer…
- Trial name
- NCT02899793
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
This research trial studies genomic analysis in tissue and blood samples from young patients with lung cancer. Identifying specific gene mutations (changes in deoxyribonucleic acid [DNA]) may help doctors tailor treatment to…
- Trial name
- NCT02273336
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV.
- Trial name
- NCT02178163
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 619 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Covid-19, Nosocomial Infection
COG-UK Project Hospital-Onset COVID-19 Infections Study
Hospitals are recognised to be a major risk for the spread of infections despite the availability of protective measures. Under normal circumstances, staff may acquire and transmit infections, but the health impact of within…
- Conditions
- Covid-19, Nosocomial Infection, Coronavirus, Coronavirus Infection
- Trial name
- COG-UK HOCI (NCT04405934)
- Testing
- Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures
- Where
- United Kingdom
- Volunteers
- 2,170 people
- Sponsor
- University College, London
Biliary Tract Cancer
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
eligible subjects will receive treatment beginning on Day 1 of each 3-week dosing cycle for pembrolizumab. Treatment with pembrolizumab will continue until documented disease progression, unacceptable adverse…
- Trial name
- NCT03110328
- Testing
- MK3475
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Thyrotoxic Periodic Paralysis
Genetic Analysis of Thyrotoxic Periodic Paralysis
Thyrotoxic periodic paralysis (TPP) is characterized by episodes of reversible hypokalemia and weakness in thyrotoxic patients. It is commonly found in males of Asian descent and is also seen in individuals having Native American…
- Trial name
- NCT00443833
- Volunteers
- 80 people
- Sponsor
- Ramathibodi Hospital
Cancer
Incidental Genomics
Health care providers (HCP) are increasingly using genomic sequencing (GS) to diagnose diseases and target treatment for patients. However, GS may incidentally reveal inherited risks for thousands of current and future diseases.
- Trial name
- NCT03597165
- Testing
- Incidental Genomic Sequencing Results, GS Results for Primary Indications only
- Where
- 3 sites in Canada
- Volunteers
- 289 people
- Sponsor
- Unity Health Toronto
Newborn, Hereditary Disease
The China Neonatal Genomes Project
The project will carry out the genetic testing of 100000 neonates in the next 5 years. The aim of the project is to construct the Chinese neonatal genome database, establish the genetic testing standard of neonatal genetic…
- Conditions
- Newborn, Hereditary Disease, Genetic Predisposition to Disease, Defect, Congenital
- Trial name
- CNGP (NCT03931707)
- Testing
- Genomic sequencing
- Where
- China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Fudan University
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.